Use for infant drug testing when only cannabinoid (marijuana) exposure is of clinical interest or when the quantity of meconium available for testing is very small (eg, <1 g).
For additional comprehensive drug testing (excluding THC), refer to Drug Detection Panel, Meconium, Qualitative (3004583).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.
Transport 0.5 g (equivalent to 1/2 inch cube) for each separate confirmation required. (Min: 0.13 g or 1/4 inch cube)
Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year
Drugs Covered: 9-carboxy-THC
Positive cutoff: 5 ng/g
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80349 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|0092316||Drug Confirmation, Cannabinoids, Mec||27024-9|